IDiyas

For the Inventor, By the Inventor

Shanghai, China

Lv Liao

USPTO Granted Patents = 14 


 

Average Co-Inventor Count = 9.6

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal14 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2014-2025

where 'Filed Patents' based on already Granted Patents

14 patents (USPTO):
1. 12466808 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2025-11-11),
2. 11530213 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2022-12-20),
3. 10947218 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2021-03-16),
4. 10844055 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2020-11-24),
5. 10710980 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2020-07-14),
6. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2019-12-17),
7. 10463653 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2019-11-05),
8. 10266531 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2019-04-23),
9. 10130629 - Pharmaceutical combinations (2018-11-20),
10. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2018-02-20),
11. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (2017-10-31),
12. 9533988 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2017-01-03),
13. 9266883 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2016-02-23),
14. 8815926 - Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases (2014-08-26),

Title: The Innovative Contributions of Inventor Lv Liao

Introduction: Lv Liao is an accomplished inventor based in Shanghai, China, renowned for his significant contributions to pharmaceutical advancements. He holds 13 patents, reflecting his dedication to innovation in the field of medicine. His work primarily focuses on developing new compounds for therapeutic uses, particularly in the treatment of arrhythmia and other medical conditions.

Latest Patents: Among his latest patents, Liao has developed two noteworthy inventions. The first is for "Naphthyridinone derivatives and their use in the treatment of arrhythmia," which provides a compound formula along with details on its manufacturing methods and therapeutic applications. The second invention, titled "Aminopyridine derivatives and their use as selective ALK-2 inhibitors," relates to a compound formula aimed at treating conditions such as heterotopic ossification and fibrodysplasia ossificans progressiva. Both patents underscore his innovative approach to addressing complex medical challenges through novel chemical compositions.

Career Highlights: Lv Liao is currently employed at Novartis AG, a leading global healthcare company known for its commitment to improving patient outcomes through innovation. His work at Novartis has positioned him at the forefront of pharmaceutical research, where his expertise in developing new therapeutic compounds is highly valued.

Collaborations: Throughout his career, Lv Liao has collaborated with distinguished colleagues, including Pascal Furet and Robert Mah. These partnerships have facilitated the exchange of ideas and knowledge, further enhancing the impact of his inventions in the scientific community.

Conclusion: Lv Liao's impressive portfolio of patents and his role at Novartis AG exemplify the profound impact that dedicated inventors have on medical innovation. Through his groundbreaking work, Liao continues to contribute to the advancement of healthcare solutions, showcasing the importance of inventors in the ongoing quest for effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…